For the Inventor, By the Inventor

Enter assignee name

Foster City, CA, United States of America

Forty Seven, Inc.

USPTO Granted Patents = 15

CIPO Patents = 5

EPO Patents = 10

Trademarks = 3

Forward Citations = 20

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Jie Liu (9 out of 40 patents)

Jens-Peter Volkmer (8 out of 30 patents)

Mark P Chao (6 out of 23 patents)

4. Ravindra Majeti (4 out of 45 patents)

5. Irving L Weissman (4 out of 146 patents)

6. Klaus Heinrich Schwamborn (3 out of 9 patents)

7. Nicola Beltraminelli (3 out of 6 patents)

8. Pierre Garrone (3 out of 11 patents)

9. Kavitha Sompalli (3 out of 3 patents)

10. Mehdi Lahmar (3 out of 3 patents)

11. Stéphanie Fallot (3 out of 3 patents)

12. Marie Châlons-Cottavoz (3 out of 3 patents)

13. Chris Hidemi Mizufune Takimoto (3 out of 3 patents)

14. Aaron Michael Ring (1 out of 35 patents)

15. Yinuo Cao (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12274746 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-04-14),

2. 12194093 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-01-14),

3. 12091458 - Humanized antibodies against c-Kit (2024-09-17),

4. 12060423 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2024-08-13),

5. 11891450 - Anti-CD47 agent-based treatment of CD20-positive cancer (2024-02-06),

6. 11802153 - Anti-CD47 agent-based ovarian cancer therapy (2023-10-31),

7. 11795223 - Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia (2023-10-24),

8. 11753480 - Anti-SIRP-alpha antibodies and related methods (2023-09-12),

9. 11643461 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2023-05-09),

10. 11208482 - Humanized antibodies against c-Kit (2021-12-28),

11. 11141480 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2021-10-12),

12. 11041022 - Humanized antibodies against c-Kit (2021-06-22),

13. 10961318 - Anti-SIRP-α antibodies and related methods (2021-03-30),

14. 10927173 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2021-02-23),

15. 10611842 - Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy (2020-04-07),

Forty Seven, Inc. is a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages to fight cancer. Their lead product candidate, 5F9, is being evaluated in multiple clinical trials for various types of cancer. The company is dedicated to advancing the field of immuno-oncology and improving outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

15 Patents

#34 in Foster City, CA

#4,865 in California

#20,400 in US

#38,669 in the World

Foster City, CA, United States of America

Forty Seven, Inc.

Forward Citations = 20

23 inventors:

Jie Liu (9 out of 40 patents)

Jens-Peter Volkmer (8 out of 30 patents)

Mark P Chao (6 out of 23 patents)

4. Ravindra Majeti (4 out of 45 patents)

5. Irving L Weissman (4 out of 146 patents)

Please report any incorrect information to support@idiyas.com

Loading…